Home > Journals > Minerva Endocrinology > Past Issues > Articles online first > Minerva Endocrinology 2022 Jul 01

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

Original Article   

Minerva Endocrinology 2022 Jul 01

DOI: 10.23736/S2724-6507.22.03663-6

Copyright © 2022 EDIZIONI MINERVA MEDICA

language: English

The role of vascular endothelial growth factor in the development of papillary thyroid carcinoma in patients with lymphocytic thyroiditis

Nese E. GULCELIK 1, 2, Safak AKIN 1, 2, Kadriye AYDIN 1, 3, Cisel AYDIN MERICOZ 4, 5, Yesim G. GULER TEZEL 4, Aydan USMAN 1, 6

1 Department of Endocrinology and Metabolism, Faculty of Medicine, Hacettepe University, Ankara, Turkey; 2 Department of Endocrinology and Metabolism, Gulhane Faculty of Medicine, University of Health Sciences, Ankara, Turkey; 3 Department of Endocrinology and Metabolism, Kartal Dr. Lutfi Kirdar Training and Research Hospital, University of Health Sciences, Istanbul, Turkey; 4 Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara, Turkey; 5 Department of Pathology, Koc University, Istanbul, Turkey; 6 Private Clinic, Endocrinology and Metabolism, Ankara, Turkey


PDF


BACKGROUND: Vascular endothelial growth factor (VEGF) plays a pivotal role in the pathogenesis of autoimmune chronic inflammatory conditions and papillary thyroid carcinoma (PTC). We hypothesized that, as VEGF expression is increased both in PTC and in lymphocytic thyroiditis (LT), it may stimulate the development of PTC in patients with LT. To evaluate this, we examined both tumor and adjacent non-tumoral tissues of PTC patients with and without LT.
METHODS: A total of 50 patients with PTC (52.50±7.41 years) and 17 patients with nodular goiter (NG) (50.47±10.38 years) were included in the study. According to the presence of LT, patients with PTC were further divided into two groups. Immunohistochemical analyses of VEGF were conducted in all patients and for PTC patients, both tumor tissue and adjacent non-tumoral tissue were evaluated.
RESULTS: The scores for intensity of staining and percentage of labeled thyrocytes for VEGF were found to be significantly higher in the PTC patients than in the NG patients (p<0.001, p<0.001, respectively). The tumor tissue revealed similar scores for PTC patients with LT and without LT. However, the scores in adjacent non-tumoral tissue were higher in PTC patients with LT than in patients without LT (p=0.004, p=0.01, respectively).
CONCLUSIONS: To the best of our knowledge, our results are the first to demonstrate that the expression of VEGF in adjacent non-tumoral tissue were higher in PTC patients with LT than in those without, which shows a possible role of VEGF expression in the progression of PTC in the presence of LT.


KEY WORDS: Thyroid cancer; VEGF; Lymphocytic thyroiditis

top of page